Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Therapeutics, IncASRT · Entity 149352 | Director | May 08, 2020 | May 12, 2020 |
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Therapeutics, Inc
Report date May 08, 2020 · Filed May 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,589 |
Reported balance
After 2020-05-08 transaction · row 1
1 source rowRow 1 · 2020-05-08 · Sale · Disposed 15,834 · Balance 84,589 F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019.
F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,816 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 92,816 F1: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Barinthus Biotherapeutics plc.
Report date September 09, 2026 · Filed September 09, 2026
Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-09 · Disposition to issuer · Disposed 1,700 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-05-01 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-09 · Disposition to issuer · Disposed 34,328 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-09 · Disposition to issuer · Disposed 18,604 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2033-05-11 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-09 · Disposition to issuer · Disposed 19,197 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2034-05-10 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-09 · Disposition to issuer · Disposed 19,516 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-09 · Disposition to issuer · Disposed 20,174 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco.
F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2020 Filed Jun 22, 2020 20:42 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,243 | $114.49 | $600,271.07 |
DisclosureSEC source: 0000899243-20-017371 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,519 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F3 · price: $114.49 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.15 to $115.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:42 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,677 | $113.58 | $304,053.66 |
DisclosureSEC source: 0000899243-20-017371 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,762 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F2 · price: $113.58 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.15 to $114.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2020 Filed May 22, 2020 01:08 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 182 | $140.29 | $25,532.78 |
DisclosureSEC source: 0000899243-20-013933 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,439 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F4 · price: $140.29 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.09 to $140.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2020 Filed May 22, 2020 01:08 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 282 | $139.40 | $39,310.80 |
DisclosureSEC source: 0000899243-20-013933 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,621 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F3 · price: $139.40 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.05 to $139.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2020 Filed May 22, 2020 01:08 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 43 | $136.98 | $5,890.14 |
DisclosureSEC source: 0000899243-20-013933 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,903 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F2 · price: $136.98 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.96 to $137.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2020 Filed May 22, 2020 01:08 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 10 | $135.91 | $1,359.10 |
DisclosureSEC source: 0000899243-20-013933 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,946 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 80 | $142.45 | $11,396.00 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 8 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,956 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 77 | $141.45 | $10,891.65 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 7 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,036 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F7 · price: $141.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.42 to $142.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 180 | $140.62 | $25,311.60 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,113 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F6 · price: $140.62 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.21 to $140.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 122 | $139.32 | $16,997.04 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,293 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F5 · price: $139.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.11 to $139.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 269 | $138.60 | $37,283.40 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,415 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F4 · price: $138.60 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.94 to $138.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 160 | $136.92 | $21,907.20 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,684 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 712 | $135.76 | $96,661.12 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,844 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F3 · price: $135.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.26 to $136.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 80 | $142.45 | $11,396.00 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 8 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,956 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 77 | $141.45 | $10,891.65 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 7 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,036 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F7 · price: $141.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.42 to $142.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 180 | $140.62 | $25,311.60 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,113 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F6 · price: $140.62 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.21 to $140.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 122 | $139.32 | $16,997.04 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,293 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F5 · price: $139.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.11 to $139.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 269 | $138.60 | $37,283.40 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,415 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F4 · price: $138.60 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.94 to $138.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 160 | $136.92 | $21,907.20 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,684 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. Read SEC document |
| May 18, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 712 | $135.76 | $96,661.12 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,844 F2 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F3 · price: $135.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.26 to $136.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 13, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,761 | $0.00 Strike: $128.18 | $0.00 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · derivative · entry 9 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,761 Underlying: Common Stock · 1,761 shares Expires 2030-05-13 F8 · derivative.exercise_date: Award vests in full one year from grant date on May 13, 2021. Read SEC document |
| May 13, 2020 Filed May 20, 2020 00:46 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 722 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013636 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,556 F1 · shares: Ms. Dawes was awarded 722 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 13, 2021. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| May 13, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,761 | $0.00 Strike: $128.18 | $0.00 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · derivative · entry 9 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,761 Underlying: Common Stock · 1,761 shares Expires 2030-05-13 F8 · derivative.exercise_date: Award vests in full one year from grant date on May 13, 2021. Read SEC document |
| May 13, 2020 Filed May 22, 2020 01:06 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 722 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013931 · doc4a.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,556 F1 · shares: Ms. Dawes was awarded 722 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 13, 2021. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| May 08, 2020 Filed May 12, 2020 00:23 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | SaleCommon Stock | 15,834 | $0.79 | $12,531.03 |
DisclosureSEC source: 0001005201-20-000037 · wf-form4_158924300983323.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,589 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,800 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-011171 · doc4.xml · derivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,800 shares Expires 2020-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable Read SEC document |
| April 21, 2020 Filed Apr 22, 2020 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 11,800 | $3.30 | $38,940.00 |
DisclosureSEC source: 0000899243-20-011171 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed May 22, 2020 01:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,800 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-013929 · doc4a.xml · derivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,800 shares Expires 2020-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable Read SEC document |
| April 21, 2020 Filed May 22, 2020 01:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 11,800 | $3.30 | $38,940.00 |
DisclosureSEC source: 0000899243-20-013929 · doc4a.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,200 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-011171 · doc4.xml · derivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 8,200 shares Expires 2020-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8,998 | $104.42 | $939,571.16 |
DisclosureSEC source: 0000899243-20-011171 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,034 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F3 · price: $104.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.72 to $104.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,202 | $104.98 | $336,145.96 |
DisclosureSEC source: 0000899243-20-011171 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,032 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020. F2 · price: $104.98 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.73 to $105.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 8,200 | $3.30 | $27,060.00 |
DisclosureSEC source: 0000899243-20-011171 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2020 Filed May 22, 2020 01:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,200 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-013929 · doc4a.xml · derivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 8,200 shares Expires 2020-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable Read SEC document |
| April 20, 2020 Filed May 22, 2020 01:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8,998 | $104.42 | $939,571.16 |
DisclosureSEC source: 0000899243-20-013929 · doc4a.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,034 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F3 · price: $104.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.72 to $104.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 20, 2020 Filed May 22, 2020 01:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,202 | $104.98 | $336,145.96 |
DisclosureSEC source: 0000899243-20-013929 · doc4a.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,032 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F2 · price: $104.98 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.73 to $105.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 20, 2020 Filed May 22, 2020 01:03 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 8,200 | $3.30 | $27,060.00 |
DisclosureSEC source: 0000899243-20-013929 · doc4a.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,849 | $97.52 | $180,314.48 |
DisclosureSEC source: 0000899243-20-005633 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,034 F4 · price: $97.52 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.20 to $98.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 906 | $99.12 | $89,802.72 |
DisclosureSEC source: 0000899243-20-005633 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,883 F3 · price: $99.12 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.50 to $99.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 945 | $99.85 | $94,358.25 |
DisclosureSEC source: 0000899243-20-005633 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,789 F2 · price: $99.85 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.50 to $100.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 300 | $101.06 | $30,318.00 |
DisclosureSEC source: 0000899243-20-005633 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,734 F1 · price: $101.06 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.85 to $101.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 23:00 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0000899243-19-017483 · doc4.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2019-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 23:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,295 | $77.35 | $100,168.25 |
DisclosureSEC source: 0000899243-19-017483 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,034 F1 · kind: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Ms. Dawes's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Ms. Dawes on April 26, 2019 in connection with the public offering of the Company's common stock. F2 · price: $77.35 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.24 to $77.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 23:00 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 20,000 | $4.96 | $99,200.00 |
DisclosureSEC source: 0000899243-19-017483 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 21:20 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | SaleCommon Stock | 12,500 | $3.18 | $39,793.75 |
DisclosureSEC source: 0001005201-19-000082 · wf-form4_156054721025442.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,423 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. F2 · price: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on June 13, 2019 at prices ranging from $3.15 to $3.23 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:11 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,953 | $0.00 Strike: $67.71 | $0.00 |
DisclosureSEC source: 0000899243-19-013993 · doc4.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,953 Underlying: Common Stock · 2,953 shares Expires 2029-05-15 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 15, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:11 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013993 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,329 F1 · shares: Ms. Dawes was awarded 1,292 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 15, 2020. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 08, 2019 Filed May 9, 2019 15:28 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000073 · wf-form4_155741568820871.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,250 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Read SEC document |
| May 08, 2019 Filed May 9, 2019 15:28 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000073 · wf-form4_155741568820871.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2019 Filed May 9, 2019 15:28 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | GrantCommon Stock | 39,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000073 · wf-form4_155741568820871.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,673 F1 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.